Ectrodactyly-Ectodermal dysplasia-Clefting (EEC) syndrome is a rare autosomal dominant disease caused by heterozygous mutations in the p63 gene and characterized by limb defects, orofacial clefting, ectodermal dysplasia, and ocular defects. Patients develop progressive total bilateral limbal stem cell deficiency, which eventually results in corneal blindness. Medical and surgical treatments are ineffective and of limited benefit. Oral mucosa epithelial stem cells (OMESCs) represent an alternative source of stem cells capable of regenerating the corneal epithelium and, combined with gene therapy, could provide an attractive therapeutic avenue. OMESCs from EEC patients carrying the most severe p63 mutations (p.R279H and p.R304Q) were characterized and the genetic defect of p.R279H silenced using allele-specific (AS) small interfering RNAs (siRNAs). Systematic screening of locked nucleic acid (LNA)-siRNAs against R279H-p63 allele in (i) stable WT-DNp63a-RFP and R279H-DNp63a-EGFP cell lines, (ii) transient doubly transfected cell lines, and (iii) p.R279H OMESCs, identified a number of potent siRNA inhibitors for the mutant allele, which had no effect on wild-type p63. In addition, siRNA treatment led to longer acquired life span of mutated stem cells compared to controls, less accelerated stem cell differentiation in vitro, reduced proliferation properties, and effective ability in correcting the epithelial hypoplasia, thus giving rise to full thickness stratified and differentiated epithelia. This study demonstrates the phenotypic correction of mutant stem cells (OMESCs) in EEC syndrome by means of siRNA mediated AS silencing with restoration of function. The application of siRNA, alone or in combination with cell-based therapies, offers a therapeutic strategy for corneal blindness in EEC syndrome. STEM CELLS 2016; 00:000-000
INTRODUCTION
Ectrodactyly-Ectodermal dysplasia-Clefting (EEC) syndrome (MIM#604292) is an autosomaldominant ectodermal dysplasia resulting from mutations in the p63 gene and characterized by limb defects, orofacial clefting, ectodermal dysplasia, and ocular defects. p63 is a transcription factor essential for the regenerative proliferation of epithelial stem cells in the skin and cornea. A healthy corneal epithelium is vital to maintain the transparency and refractive state of the cornea, which are essential for normal vision and ocular comfort. The corneal epithelium is a stratified epithelium from which superficial terminal cells are naturally shed, and the a Research Centre, Fondazione Banca degli Occhi del Veneto, 30174 Venice, Italy; lost corneal epithelial cells are replaced by stem cells located at the edges of the cornea, in a region known as the limbus. The stem cells for the corneal epithelium are, therefore, more commonly known as limbal epithelial stem cells (LESCs) because of their anatomical location. The p63 gene generates six isoforms and DNp63a is the predominant isoform in the human corneal epithelium [1] . DNp63a is necessary for the maintenance of the proliferative potential of LESCs and essential for regenerative proliferation in the ocular surface. The major cause of visual morbidity in EEC syndrome is limbal stem cell deficiency (LSCD) and we recently reported that the diminished ability of LESCs to regenerate fully stratified corneal epithelia is related to p63 mutations [2, 3] .
LSCD is characterized by conjunctival epithelial ingrowth, neovascularization, recurrent corneal erosion, and persistent ulcers, as well as corneal scarring [2, 4] and ultimately leads to visual impairment and blindness. Transplantation of autologous LESC grafts has shown to be successful for the treatment of acquired unilateral LSCD, but it is not feasible in cases of bilateral LSCD, as in the EEC syndrome [5, 6] . Transplantation of allogenic limbal epithelium is possible, but requires systemic immunosuppression and it has a success rate that decreases gradually over time (graft survival rate of 40% at 1 year and 33% at 2 years) [7] . For patients with bilateral LSCD, transplantation of cultured autologous oral mucosal epithelial cell sheets might be the only effective alternative for reconstructing the ocular surface [8, 9] . Numerous studies have shown that oral mucosal epithelial stem cells (OMESCs) are a feasible alternative to limbal transplants [8] [9] [10] , and an ideal substitute of LESCs in ocular surface reconstruction [11] .
Given that five p63 mutations account for almost 90% of EEC cases and that the arginine (R) residues at position 304 (R304) and 279 (R279) are mutational hotspots, gene silencing or editing strategies are required for a limited number of targets, making this approach an efficient strategy applicable to the majority of EEC patients. As EEC syndrome results from heterozygous dominant-negative mutations in the p63 gene therapeutic strategies based on allele-specific (AS) gene silencing through RNAi could specifically inhibit the expression of disease-associated alleles without suppressing the expression of the corresponding wild-type (WT) alleles to phenotypically correct the stem cell population restoring function. Here, we characterize OMESCs from patients with EEC syndrome and demonstrate a proof-of-principle approach to correct the underlying genetic defect by AS gene silencing. Phenotypic correction of mutant p63 in OMESCs using small interfering RNA (siRNA) mediated AS silencing restored full thickness stratification and differentiation of the epithelia. This study supports the application of siRNA, alone or in combination with cell based therapies as a therapeutic strategy for corneal blindness in EEC syndrome.
MATERIALS AND METHODS

Cell Culture
Primary human keratinocytes were isolated from fresh oral mucosal biopsies of a healthy subject (aged 24) and two EEC patients (both patients were 18 years old) after an informed consent form was signed. The research program and the informed consent forms were approved by the Venetian Ethical Committee for Clini- Once isolated, cells were cultivated as previously described [12, 13] . The calculation method used for cell doublings and cumulative population doublings was: 3,322*log 10 (UCY/I), where UCY 5 the cell yield at that point and I 5 number of clonogenic cells. The clonogenic cells were calculated as the cell number used as inoculum to begin that subculture multiplied by the colony forming efficiency (CFE) value. Human embryonic kidney cells stably transduced to express the simian virus 40 T antigen (293T) were provided by D. Baltimore (Rockefeller University, New York, NY).
Cell Proliferation Assay
The assay was performed in Silicone Culture-Insert in a 35-mm dish that creates a 0.5-mm gap across the diameter of the well (Ibidi, Madison, WI). Primary cells were cultured until confluence, then the insert was removed and the cell proliferation across the gap monitored over time using A1Rsi 1 Laser Scanning Confocal Microscopy (Nikon Instruments Inc., Melville, NY).
[Ca
21
] i Measurements [Ca 21 ] i was measured by single-cell computer-assisted videoimaging using A1Rsi 1 Laser Scanning Confocal Microscopy (Nikon Instruments Inc., Melville, NY), as described before [14] . Briefly, 3.5 3 10 5 OMESCs cells were plated one day prior to transfection on glass coverslips, covered with UV-irradiated 3T3 cells, in 35-mm dishes. Cells were loaded with 4 lM Fluo-4/AM (Molecular Probes, San Diego, CA; stock solutions of 1 mM in dimethyl sulfoxide (DMSO), stored in aliquots at 220 8C). Transfected cells were visualized using a 543-nm laser line (emission 570-600 nm) and selected for analysis. Images were acquired every 4 s and stored for offline analysis. Twenty to thirty-five individual cells were selected and monitored simultaneously from each coverslip. Fluo-4 fluorescence intensity was expressed as an F i /F basal -ratio, where F i is the background subtracted fluorescence intensity and F basal is the background subtracted mean fluorescence value measured from each cell at rest. All experiments were performed at room temperature.
Hemicornea Preparation In Vitro
Human Keratoplasty Lenticules (HKLs) were prepared as previously described [15] . Briefly, corneoscleral rims were preserved at 4 8C and used within 1-2 days from their excision. Each specimen was firmly placed in an artificial chamber and the epithelium manually removed after bathing the surface of the cornea with an isotonic solution containing 5 mg/ml of trypsin and 2 mg/ml of EDTA HKLs were obtained by microkeratome resection of epithelium-free corneas. Epithelial stem cells were plated onto HKLs at a concentration of 5 3 10 4 cells/cm 2 . Hemicorneas were cultured under submerged conditions for 7 days and air-lifted for 14 further days.
Histology and Immunofluorescence
Hemicorneas were fixed in 4% paraformaldehyde, embedded in Optimal Cutting Temperature compound, frozen, and sectioned. Sections (5-7 lm) were analyzed using antibodies against DNp63a (rabbit polyclonal, 1:200; PRIMM, Milan, Italy), keratin 3 (AE5 clone, mouse monoclonal, 1:100; MP Biomedicals, Solon, OH), 14-3-3r (rabbit polyclonal, 1:400; PRIMM), involucrin (goat polyclonal, 1:100; Santa Cruz Biotechnology, Santa Cruz, CA), laminin-b3 (goat polyclonal, 1:200; Santa Cruz Biotechnology, Santa Cruz, CA) 
Vectors
The human WT-DNp63a and R279H -DNp63a encoding regions were obtained by reverse transcriptase-polymerase chain reaction (RT-PCR) performed on total RNA from p.R279H-OMESCs, employing specifically designed primers containing BamHI (PB1) and PstI (R/C), respectively, at the 5 0 and 3 0 end and cloned into the pCR2.1 TOPO-TA cloning plasmid. The red fluorescent protein (RFP) encoding sequence was amplified from the pTAG-RFP-T plasmid [16] , while the EGFP fragment was derived from pcDNA3.1eGFP by polymerase chain reaction (PCR). The obtained PCR fragments, containing the PstI and the EcoRV restriction sites at the 5 0 and 3 0 end, respectively, were cloned in the pCR2.1 TOPO-TA cloning plasmid leading to TOPO-RFP and TOPO-eGFP constructs, respectively. The internal ribosome entry site (IRES)-Blasticidine cassette was amplified by PCR using as a template the pWPI-blr employing primers IB5 0 , containing an EcoRV restriction site at the 5 0 end and IB3 0 , containing an XhoI restriction site at the 3 0 end [17] . The PCR fragment was cloned in the pcR2.1 TOPO-TA cloning plasmid (TOPO-IRES-BLAST). The final pCDNA 3.1-based plasmids were constructed by ligating into the backbone digested with BamH1-EcoRV, the WT-DNp63a or R279H-DNp63a BamHI-PstI fragments, derived from the pCR2.1-DNp63a or DNp63a R279H, respectively. Expression is driven by the CMV promoter. The lentiviral vectors were generated by digesting a pRRL.SIN-18.cPPT.CMV.GFP.WPRE backbone with BamHI-Sal I and the following fragments inserted: (i) WT-DNp63a or R279H-DNp63a as a BamHI-PstI fragment derived from the pCR2.1-DNp63a or DNp63a-R279H, respectively; (ii) RFP or EGFP cassette as a PstI-EcoRV fragment derived from TOPO-RFP or TOPO-EGFP, and (iii) EcoRV-XhoI fragment containing the IRES-Blasticidine obtained from the TOPO-IRES-Blasticidine. All the plasmid-cloned fragments were confirmed by sequencing.
Production of Lentiviral Particles
Production of third generation HIV-derived vectors was achieved by transient cotransfection of four plasmids into 293T epithelial cell line [18] . The HIV-derived packaging constructs were pMDLg/pRRE and RSV-Rev, which contain: (i) the group-specific antigen (gag) and pol genes under the control of a cytomegalovirus (CMV) promoter and polyadengylation site of the human b-globin gene; (ii) the rev cDNA. VSV G was expressed from pMD.G, meanwhile the transfer constructs expressing the human WT DNp63a-RFP or R279H-DNp63a-EGFP downstream CMV promoter were pRRL.SIN-18. Forty-eight hours after transient transfection of the four plasmids into HEK293T cells by Lipofectamine 2000 (Life Technologies, Carlsbad, CA), supernatants were collected and then stored at 280 8C.
Transduction with Recombinant HIV Particles
HEK293T cells were seeded onto 12-well tissue culture plates at a density of 4 3 10 5 and transduced with recombinant viral particles using a range of serial dilutions. After 3 days, DNAs were analyzed by quantitative PCR, calculating the copy number of HIV sequences using primers and probes for GAG and GADPH detection. Titers were around of 10 6 -10 7 transducing units/ml for each viruses.
Development of Stable Human DNp63a Cell-Lines
HEK293T cells (6 3 10 6 ) were seeded onto 10-cm tissue culture plates and transduced with recombinant viral particles using a range of 0.5-1 multiplicity of infection (MOI). After 3 days, transduced cells were exposed to complete Dulbecco's modified Eagle's medium supplemented with Blasticidin S HCl, at a concentration of 10 mg/ml. After about 2 weeks of selection, the arising clones were detached and subcloned into 24-well plates for imaging selection. Clones showing a p63 nuclear staining comparable to that of primary keratinocytes were expanded for further characterization.
Western Blot
Whole cell lysates for western blot were analyzed with the following primary antibodies: pan-p63 (4A4, mouse monoclonal, 1:500, Dako, Milan, Italy), p16 ink4a (mouse monoclonal antibody, 1:500, Exalpha Biologicals, Shirley, MA), DNp63a (rabbit polyclonal, 1:200; PRIMM, Milan, Italy), and GAPDH (rabbit polyclonal, 1:1000; Santa Cruz Biotechnology, Santa Cruz, CA). The band intensities were quantified using an Image J analysis software. The relative amount of p63 protein was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
Real-Time qPCR Assays
Total RNAs from primary keratinocytes and 293T cells were extracted and purified using the RNeasy Micro kit (Qiagen, Hilde, Germany). For the absolute DNp63a quantification (AbqPCR), the level of expression of the target gene was normalized to (GAPDH). For the relative gene expression analysis (RelqPCR), the difference in relative p63 expression was performed using the 2 2DDCt method. GAPDH was used as internal control gene. The percentage of WT or mutated mRNA DNp63a expression was measured by means of allele-specific real time (ASqPCR) assay [3] . Primers and probes are shown in Table 1 .
siRNA Sequence Walk and Transfection
All possible siRNAs (n 5 19) were designed to target the R279H-p63 mRNA region containing a single-nucleotide change (G-A at nucleotide position 953 resulting in the amino acid change, R279H). They: (i) have a sequence of 19 nucleotides; (ii) incorporate the locked nucleic acid (LNA); (iii) were obtained as single stranded from Exiqon (Exiqon, Vedbaek, Denmark) and prepared as reported [19] . All siRNAs were transfected into (i) 293T cells stably expressing either the human DNp63a or DNp63a-R279H, (ii) serially propagated primary keratinocytes, and (iii) organotypic cultures with Lipofectamine 2000 (Life Technologies, Carlsbad, CA).
Dose Titration Analysis
Titration of siRNA a was performed using a narrow range of siRNAs from 0.1 to 10 nM in 293T HEK DNp63a stable cell lines and from Barbaro, Nasti, Del Vecchio et al. 
Statistical Analysis
All data are reported as mean 6 S.E.M. When comparing two data sets, the Student's t test for unpaired data was used. To compare multiple groups, statistical comparisons were performed with one-way or two-ways ANOVA followed by TukeyKramer post hoc test. Significance is at p < .05. Statistical comparisons were carried out using the Graph-PAD 3.02 software suite (GraphPad Software Inc., San Diego, CA).
RESULTS
p63-Defective Oral Epithelial Cells Undergo a Rapid Exhaustion of Clonogenic and Self-Renewal Potential, Resulting in Accelerated Ageing
To investigate how p.R279H and p.R304Q p63 mutations affect LESC physiology in EEC syndrome, OMESCs from healthy (H-OMESCs, n 5 1) or EEC individuals (EEC-OMESCs, n 5 2, with heterozygous p.R279H and p.R304Q p63 mutations) were isolated from oral mucosal biopsies and serially propagated until exhaustion. Compared to H-OMESCs, EEC-OMESCs showed (i) a more rapid decrease of CFE and clonogenic cell numbers (Fig.  1A, 1B) , (ii) progressive increased percentage of aborted colonies during serial cultivation (Fig. 1C) , and (iii) increased replicative senescence, as suggested by the lower number of cell passages in culture (Fig. 1D) . As previously reported in papers describing the effects of the loss of p63 [20, 21] , cell growth was faster in EEC-OMESCs, with cultures becoming confluent in 4-5 days compared to 6-7 days observed in H-OMESCs controls. In addition, we also observed that EEC-OMESCs proliferate at a faster rate compared to controls, both at 4 h or 7 h after the insert was removed (Fig. 1E) . Percentage of wound closure was also increased in EEC-OMESCs compared with H-OMESCs; specifically H-OMESCs showed 1.0 6 0.2% and 32 6 4% closure at 4 h and 7 h, respectively, whereas p.R279H OMESCs showed 6 6 1% and 58 6 3% closure at 4 h and 7 h, respectively and p.R304Q OMESCs 15 6 1% and 86 6 7% closure at 4 h and 7 h, respectively (Fig. 1F) . To demonstrate that p63 mutant cells undergo accelerated ageing, we performed a senescenceassociated-beta galactosidase staining (Fig. 1G ) and western blot of p16 and DNp63a at different cell passages (1 and 7) (Fig. 1H ) in H-OMESCs, p.R279H-OMESCs, and p.R304Q-OMESCs.
Mutations in p63 Lead to Abnormal Stratification of Epithelia and Differentiation Pathways
We evaluated the ability of p63-defective EEC-OMESCs to stratify and differentiate in a HKL model [15] . Primary healthy, p.R279H, and p.R304Q OMESCs at passage two were seeded onto HKLs and grown for 21 days. Compared to H-OMESCs controls, epithelia generated by EEC-OMESCs were hypoplastic with defects in epithelial thickness and cellularity with some areas devoid of cells and with flat irregular and terminally differentiated cells ( Fig. 2A) 
Abbreviations: Ab-qPCR, absolute quantitative PCR; ASqPCR, allele-specific quantitative PCR; GAG, group-specific antigen; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GFP, Green Fluorescence Protein; RFP, red fluorescent protein. Correction of EEC Defects by Gene Silencing
STEM CELLS differentiated cells, as indicated by the expression of keratin 3 and involucrin, (iii) suprabasal cuboid wing cells, expressing 14-3-3r, an early differentiation marker for stratified epithelia, and (iv) proliferating cells, expressing Ki67 (Fig. 2B) . The basal cuboidal cell layer was firmly attached to the underlying extracellular matrix and to the basement membrane (Fig. 2B,  top panel) . In contrast, tissues generated from EEC-OMESCs showed defects in both stratification and differentiation, thus resulting in severe tissue hypoplasia and lack of proper tissue polarity (Fig. 2B , middle and bottom panels), but not in Barbaro, Nasti, Del Vecchio et al. proliferation (Ki67 is similar in EEC and healthy cells). We also observed anomalous clusters of terminally differentiated cells strongly expressing keratin 3 and involucrin (terminal differentiation marker for stratified epithelia), but not p63 and low 14-3-3r, indicative of a premature terminal differentiation phenotype (Fig. 2C) . As previously reported [22] , we also observed reduced adhesion properties of the epithelium obtained by mutant cells (Fig. 2B, 2C ). Cells are known to progressively lose sensitivity to extracellular calcium as they proceed further along the differentiation process [23] [24] [25] [26] [27] [28] [29] [30] . Since EEC-OMESCs display defective differentiation and stratification, we speculated that cellular calcium cycling is altered in cells expressing p63 mutants. Specifically, we analyzed capacitative calcium entry, one of the main calcium influx pathway of not-excitable cells, in H-OMESCs and EEC-OMESCs (at the third passage, when differentiation has already developed). When intracellular calcium store was depleted to activate capacitative channels [31] , we found that, compared to H-OMESCs controls, the capacitative calcium entry was significantly reduced both in p.R279H and p.R304Q OMESCs, as a likely consequence of the premature accelerated differentiation of the mutated cells (Supporting Information Fig. 1 ).
DNp63a Expression in Cells from Healthy and p.R279H EEC Donors
Given that p63 accumulation, due to higher stability of the EEC mutated isoform, has been previously observed in tissues Hematoxylin-eosin staining of epithelia generated on human keratoplasty lenticules by healthy, p.R279H and p.R304Q primary OMESCs at passage 2 (n 5 3, scale bars 5 50 lm). (B): Double-immunofluorescence on epithelia derived from the above OMESCs using p63(red)/ K3(green), 14-3-3r (red, Ki67 (green), and involucrin (orange) antibodies (n 5 3, scale bars 5 20 lm). (C): Immunofluorescence performed on the anomalous clusters of terminally differentiated p.R279H OMESCs using p63 (red), K3 (green), involucrin (orange), and 14-3-3r (red) antibodies (n 5 3, scale bars 5 50 lm). Abbreviations: OMESCs, oral mucosa epithelial stem cells; K3, keratin 3. 
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of patients affected by EEC syndrome [32] , DNp63a expression in p.R279H OMESCs was quantified using an absolute quantitative PCR at different passages in culture (I, III, V, VII, and XI) and compared to H-OMESCs and healthy-limbal epithelial stem cells (H-LESCs). As shown in Figure 3 , DNp63a decreased during serial cultivation, becoming very low after the seventh passage. The rate of reduction was faster in p.R279H OMESCs, compared to H-OMESCs and H-LESCs. DNp63a expression was threefold higher in p.R279H OMESCs compared to HOMESCs, at the first passage. This correlates well with the abnormal hyperproliferation of p.R279H EEC primary cells, previously observed in the CFE and cell proliferation assays (Fig. 1A,  1E ). This most likely results from an impaired negative regulatory loop, which is DNp63a-dependent, needed for cell-cycle arrest, and for the initiation of a differentiation program [33] . Importantly, the amount of DNp63a in primary H-LESCs was approximately two times lower than in H-OMESCs. This correlates well with their "cumulative population doubling ability" observed in vitro (H-LESCs 5 10 6 2 passages; H-OMESCs 5 12 6 2 passages) [34] and reflects the different "intrinsic lifespan" and "clonogenic potential" of the two cell lineages. Our findings confirm that DNp63a is a robust stem cell marker: (i) its expression declines during the differentiation and senescence processes of primary epithelia stem cells in vitro and (ii) also provide further evidences of the premature differentiation found in EEC-OMESCs. To gain greater insight into the relationship between DNp63a expression and EEC pathogenesis, we evaluated the percentage of WT or mutated mRNA p63 expression through allele-specific quantitative PCR (AS-qPCR). ASqPCR demonstrated that the profile expression ratios of two transcripts were different in three passages analyzed (I, III, and V) with a decrease of the mutated p63 mRNA (Fig.3, green and red indicate mutant and WT expression levels, respectively). At the first passage, the percentages of mutant R279H p63 mRNA and WT p63 mRNA were 60 6 7% and 40 6 5% respectively, while during the differentiation process, these ratios decreased to 12 6 1.7% and 23 6 0.9%, respectively.
Establishment of a p.R279H EEC Model System
To screen the efficiency of siRNAs to block the expression of mutant p63 with little or no effect on WT p63, we established two cellular models stably expressing WT-DNp63a or R279H-DNp63a HEK293T cells, an epithelial cell line with no endogenous p63 expression, were transduced with third generation lentiviruses carrying WT-or R279H-DNp63a alleles fused to RFP or EGFP sequences, respectively (Fig. 4A) . After the isolation of stable clones (n 5 14 for both constructs), we observed that all the cell lines carrying the R279H-DNp63a allele showed higher levels of DNp63a expression, at the mRNA expression level, than control clones expressing WT-DNp63a (Supporting Information Fig. 2A) . Considering that (i) both WT than R279H-DNp63a cell lines were obtained using the same transduction and selection conditions and (ii) the same results were also obtained after transient transfection, the hypothesis is that our cell model mirrors the higher amount of R279H-DNp63a, previously found and described ex vivo in p.R279H OMESCs. To test our hypothesis and screen the ability of siRNAs to counteract the R279H-p63 expression, we chose two clones (WT#9 and R279H#2) that exhibited the typical nuclear localization signal of DNp63a and expressed, in toto, mRNA and protein levels of DNp63a comparable to the endogenous level found in EECOMESCs (Supporting Information Fig. 2A, 2B ).
Systematic Screening of LNA-siRNAs Against the R279H-p63 Allele
Stable cell lines were used to separately transfect a collection of 19 LNA siRNAs [35, 36] , designed to target the R279H-p63 mRNA region containing the single nucleotide change. Fortyeight hours post siRNA transfection, AS downregulation was assessed through DNp63a relative-qPCR. siRNAs (a, b, and c) specifically downregulated the R279H-DNp63a mRNA by approximately 90% (Fig. 4B) . Interestingly, some siRNAs upregulated R279H-DNp63a (r and s), suggesting an interference with the DNp63a post-transcriptional regulation pathway. No changes in cell viability were observed after siRNA transfection. Western-blot analyses demonstrated a significant and specific reduction of mutant DNp63a protein when siRNA a was used (45 6 4%), while protein downregulation with siRNA b and siRNA c did not have consistent and reproducible effects (Fig.  4C, 4D ). Imaging analyses of the two HEK293T-DNp63a stable lines treated with doses of siRNA a ranging from 0 to 10 nM (0, 0.1, 1, and 10 nM) showed that compared to a nontargeting control siRNA (siNCT; negative control), siRNA a (i) reduced the expression of R279H-DNp63a-EGFP protein in a concentrationdependent way, reaching 43 6 5% at 10 nM, (ii) maintained the fluorescence of the WT-DNp63a-RFP protein, and (iii) had an IC 50 of 3.15 6 0.79 nM, showing a potent inhibitory effect in vitro (Supporting Information Fig. 2C-2E) .
To evaluate the specificity of siRNA a to (1) inhibit the R279H-DNp63a neo-synthesis, and (2) downregulate its expression in time-dependent manner, we utilized transiently transfected HEK293T cell lines, as an in vitro cellular model of the EEC disease-related heterozygous state. The HEK293T cell line was cotransfected with a 1:1 ratio of both WT-DNp63a-RFP and mutant DNp63a-EGFP plasmids in the presence of the siRNA a. We observed a specific and significant neo-synthesis inhibition of R279H-DNp63a-EGFP expression in approximately 80% of total cells at 48 h post transfection when compared to siNCT- Barbaro, Nasti, Del Vecchio et al. treated cells (Fig. 4E-4G) . In further experiments, siRNA a was subsequently added to transiently cotransfected cells, together with fluorescein labeled siRNA (FITC-siRNA) to follow the delivery of the siRNAs. Z-stack imaging and orthogonal analyses of the fluorescent cells showed a specific time-dependent silencing of R279H-DNp63a-EGFP. Forty-eight hours post transfection a maximum effect was observed in siRNA a 1 FITC-siRNA targeted cells (Fig. 4H) . We further wanted to validate the inhibitory potential of our most discriminating and potent AS siRNAs ex vivo. To estimate the transfection efficiency of siRNAs in human OMESCs and to allow direct observation of their cellular uptake, distribution, and localization, primary p.R279H OMESCs were transfected using concentrations of FITC-siRNA ranging from 10 to 100 nM (10, 25, 50, 75, and 100 nM). Forty-eight hours post transfection, the optimal transfection efficiency was of 88 6 2% at 100 nM (Fig. 5A) . Subsequently, we serially transfected the siRNA c, siRNA a, and siRNA b in the primary p.R279H OMESCs at 100 nM, and the expression levels of WT and R279H-p63
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were measured using AS-qPCR. Amplification plots of WT (blue curves) and mutated mRNA (green curves) output from (i) siNCT, (ii) siRNA c, (iii) siRNA b, (iv) siRNA a, and (v) the H-OMESCs samples are shown in Figure 5B . Significant suppression of mutant mRNA occurred with siRNA a, and also with siRNA b and c, which suppressed mutant mRNA levels up to 80%, 72%, and 65% with respect to untreated cells, respectively. To determine the minimum concentration of siRNA a needed to knockdown the R279H-p63 mRNA, a dose-response (concentration) analysis was performed within a narrow range of 0, 1, 10, and 100 nM and the transcript levels evaluated with AS-qPCR. As shown in Figure 5C , titration of siRNA a abolished the R279H mRNA, showing a gradient of values which correlated with the concentration used, with an IC 50 of 7.20 6 0.04 nM (Fig. 5D) . siRNA a was, therefore, able to downregulate the mutated allele without altering the expression of the WT-DNp63a both in vitro and ex vivo.
Restoration of Premature Clonogenic and Proliferative
Arrest in R279H-p63 Primary Cells by Long-Term siRNA a Treatment
To investigate whether siRNA a could restore the functional phenotype in p.R279H OMESCs, we repeated the cell proliferation assays with OMESCs treated with either siNCT or siRNA a (at 100 nM). Imaging analyses revealed that the wound closure at 4 and 7 h was reduced in p.R279H OMESCs treated with siRNA a, but not with siNCT, and the closure kinetics were more similar to control H-OMESCs (Fig. 5E, 5F ). Furthermore, p.R279H OMESCs treated with siRNA a (but not with siNCT) had a longer life-span and were able to be passaged in culture seven times compared to 5-6 with H-OMESCs. Finally, siRNA a treatment specifically mitigated the progressive loss of clonogenic cells in p.R279H OMESCs, and a trend more similar to H-OMESCs was achieved (Fig. 5G) , as also confirmed by the results of the CFE assay (Fig. 5H) . At the concentration of siRNA used, no significant alterations were observed in both the keratinocyte morphology and the expression level of markers such as p63, DNp63a, MUC1, K3, K4, and K13 in siRNA a-treated OMESCs.
Impaired Epithelial p.R279H OMESCs Stratification and Differentiation is Rescued by siRNA a Infusion
To test the ability of siRNA a to restore the epithelial tissue phenotype, two simultaneous organotypic cultures of p.R279H OMESCs were established using a device able to create two different and separated areas in a single HKL (Fig. 5I) . One area was treated with siRNA a and the adjacent with a scrambled siRNA (siNCT) (Fig. 5J) . FITC-siRNAs were also added to track distribution. At the end of the culture, histological sections of the tissues were taken to assess the ability of p.R279H OMESCs to correctly stratify following siRNA a treatment (Fig. 5K ) and compared to control (Fig. 5L) . Confocal microscopy demonstrated the presence of a well-organized and stratified epithelium of 4-5 layers limited to the area treated with siRNA a, while the adjacent region showed the typical phenotype of the p63-mutated cells. The resulting epithelium was characterized by basal expression of p63 and DNp63a while expression of keratin 3 and 14-3-3r was mainly found in the upper cell layers. The basal cuboidal epithelial cells were anchored to the basement membrane and expressed b3-laminin.
DISCUSSION
AS gene silencing has previously been described for the treatment of Amyotrophic Lateral Sclerosis [37, 38] and other genetic diseases [39, 40] . For the cornea, AS siRNAs have been successfully developed against the mutant allele of the KRT12 gene for a severe form of Meesmann Epithelial Corneal Dystrophy [41] . AS siRNAs represent a potential approach to treat the heterozygous dominant-negative p63 mutations which result in EEC syndrome and corneal blindness due to LSCD. In this study, we characterized OMESCs from patients with EEC syndrome and demonstrated a proof-of-principle approach Laser scanning confocal microscope images of the wound healing assay, performed on healthy (H-OMESCs) and ectrodactyly-ectodermal dysplasia-clefting donors cells (p.R279H-OMESCs), with control (siNCT) or siRNA a treatment, at the indicated time after the silicone insert was removed. Images are representative of at least two independent experiments. (F): Quantification of the wound closure assay. Data indicate the percentage of the wound closure relative to the total area of the scratch. All data are expressed as mean 6 SEM and derived from at least two independent experiments. *p < .05, ***p < .001. (G): Colony forming efficiency (CFE) assay of WT-p63 and p.R279H OMESCs, continuously exposed to siNCT or siRNA a, evaluated at the cell passages indicated. siRNA a effectively reestablishes the clonogenic ability and proliferation property of the p63 mutant cells. All data are expressed as mean 6 SEM and derived from at least three independent experiments. *p < .05, **p < .01. to correct the underlying genetic defect in p63 using AS gene silencing. Since transplantation of OMESCs has previously shown to be a valid alternative for reconstructing the ocular surface in bilateral LSCD patients, we initially characterized OMESCs isolated from two EEC patients carrying the most severe mutations affecting the cornea: p.R279H and p.R304Q. Compared to controls, both mutants showed (i) premature clonogenic and proliferative stop; (ii) increased replicative senescence; (iii) altered wound healing properties; (iv) reduction of the capacitative calcium entry and (v) defects in stratification and differentiation, thus resulting in severe epithelial hypoplasia and lack of proper tissue polarity. These characteristics explain some of the clinical features of the ocular surface seen in EEC patients: progressive conjunctivalization of the cornea, recurrent corneal erosions, and ulcers that get worse along with the years. Characterization of OMESCs and AS gene silencing experiments allowed us to make two important findings. First, OMESCs display a higher self-renewal potential than LESCs, thus supporting further their use as an alternative source of cells for the treatment of LSCD. Second, consistent with the finding that mutant R279H p63 mRNA is more stable than WT [32] , we found that DNp63a accumulates in OMESCs carrying the p.R279H mutation and its expression declines during the differentiation and senescence processes of primary cells in vitro faster than in WT cells. Considering the role of DNp63a in LESCs [1] [2] [3] [4] [5] [6] , this misregulation may have the functional consequence to induce a premature stop to cell proliferation and to allow the alteration of the differentiation pathway. The accumulation of DNp63a in p.R279H OMESCs is, at least in part, due to the increased stability of the transcriptionally inactive R279H mutant [32] , that negatively interferes with the p63 autoregulatory loop active in stem cells [42] . The specific silencing of the mutated allele may, therefore, have several advantages and reduce both the amount of transcriptionally inactive p63 and the inhibition of the transactivation of the WT p63, mediated by the R279H protein, which is necessary for the activation of the autoregulation loop. All our experiments pointed toward the efficacy and efficiency of siRNA a, as the R279H-DNp63a-mutant protein was specifically knocked down by approximately 80% while the WT was stably expressed and unaffected. In addition, siRNA a-treated p.R279H OMESCs showed longer life-spans, reduced proliferation properties, and effective ability in correcting the epithelial hypoplasia, thus giving rise to a full thickness stratified and differentiated epithelia.
Depending on the timing and severity of LSCD, our results might have clinical applications both for young and adult EEC patients. EEC-related corneal pathology follows a clear clinical course with LSCD usually manifesting in the second to third decade leading to severe corneal failure in the fourth to fifth decade [2] . This provides a therapeutic window to correct the genetic defect using genetic preventive strategies, which could maintain corneal clarity, prevent blindness, and obviate pain and photophobia. In early corneal disease, with LESCs still present in the limbus, the use of eye drops containing mutantspecific siRNAs may be a practical therapeutic option. In patients with established LSCD and no limbal stem cell population, clinical outcomes may be improved by ex vivo gene correction of OMESCs with p63 mutant-specific siRNAs (Fig. 6) .
CONCLUSIONS
In summary, we truly believe that our strategy could provide a therapeutic window to correct the EEC defect and the use of genetic preventive strategies could counteract the premature differentiation and the clinical downstream effects of limbal stem cell deficiency usually seen in EEC patient. Our findings could also be applicable to other genetic disorders affecting the ocular surface (e.g., aniridia and corneal dystrophies, such as Meesmann).
